Ipamorelin
Selective growth hormone secretagogue with minimal side effects.
What Is Ipamorelin?
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It stimulates growth hormone release with high selectivity, meaning it does not significantly raise cortisol or prolactin levels. Often stacked with CJC-1295 for synergistic effects.
🔬 Mechanism of Action
Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist and growth hormone secretagogue peptide. It stimulates GH release from the anterior pituitary by activating the growth hormone secretagogue receptor pathway, producing discrete GH pulses without significantly elevating cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier GH secretagogues such as GHRP-2 and GHRP-6. Its specificity is attributed to the absence of activity at non-GHSR receptor targets involved in stress hormone secretion.
Effectiveness Profile
Relative effectiveness scores derived from published preclinical literature across key endpoints.
Scores are qualitative aggregates from animal and in vitro studies and are not a medical claim. For educational purposes only.
Applications & Benefits
Key Study Findings
Produces dose-dependent GH pulses with minimal effect on cortisol or prolactin in pharmacological studies
Shown to increase IGF-1 levels following repeated administration in preclinical models
Exhibits favorable selectivity compared to GHRP-2 and GHRP-6 based on hormonal response profiling
Studies in aged rats demonstrate restoration of GH pulse amplitude toward levels observed in young animals
Synergistic GH release observed when combined with GHRH analogs such as CJC-1295 in studies protocols
Effect Timeline
Expected milestones based on published preclinical data.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
First amplified GH pulses detected. Slight IGF-1 elevation begins; anabolic signaling pathways activate.
IGF-1 levels plateau at elevated baseline. Protein synthesis increases; recovery from training improves noticeably.
Lean mass accumulation measurable. Fat oxidation increases; sleep quality improvements typically reported.
Maximum body composition improvements at sustained elevated GH/IGF-1 levels. Anti-aging mechanisms fully engaged.
Timelines are derived from preclinical animal studies. Individual results in laboratory settings may vary. For educational purposes only.
Dosing Protocol
Dosing information is derived from published animal studies and is provided for educational purposes only.
Reconstitution Calculator
Calculate exact BAC water volume and dose measurements for Ipamorelin.
For laboratory use only. This calculator is a reference tool — verify all calculations before use. Always use sterile technique with bacteriostatic water and sterile syringes.
Synergistic Stack Combinations
Key Scientific Literature
Ipamorelin, a new growth hormone releasing peptide, selectively stimulates growth hormone secretion
Key finding: Ipamorelin produced potent, dose-dependent GH release with no effect on cortisol, prolactin, or ACTH — confirming high selectivity.
Long-term effect of ipamorelin on body weight and composition
Key finding: Chronic Ipamorelin administration significantly increased lean body mass and reduced fat mass in animal models.
Citations reference published peer-reviewed studies. This is not a complete literature review. All studies were conducted in preclinical or controlled clinical settings. Content is for educational reference only.
Frequently Asked Questions
What makes ipamorelin more selective than other GHRP peptides?
Ipamorelin was specifically designed to activate the GHSR-1a receptor without stimulating the release of cortisol, prolactin, or ACTH — side effects associated with earlier GH secretagogues like GHRP-2 and GHRP-6. This selectivity is attributed to its lack of agonist activity at receptors involved in the HPA stress axis. The result in preclinical models is a cleaner GH pulse profile.
How does ipamorelin produce GH pulses?
Ipamorelin mimics the action of ghrelin by binding GHSR-1a receptors on pituitary somatotroph cells, triggering intracellular calcium mobilization and GH vesicle release. Unlike continuous GH elevation, ipamorelin produces discrete pulses that more closely resemble physiological GH secretion patterns. Studies show peak GH levels approximately 15–30 minutes post-injection in animal models.
Can ipamorelin be combined with GHRH-class peptides in studies?
Yes, combination protocols using ipamorelin alongside GHRH analogs such as CJC-1295 or sermorelin are well-documented in studies literature. The two classes act on separate receptor systems, and concurrent administration has been shown to produce synergistic GH release exceeding what either peptide achieves alone. This dual-receptor approach is a common design in GH secretagogue protocols.
Related Topics
Ipamorelin
For educational use only · Verified vendor
